{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:35:40Z","timestamp":1757619340824,"version":"3.44.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-025-02670-y","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T08:31:12Z","timestamp":1753173072000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiply doses of FDC of rosuvastatin and ezetimibe versus rosuvastatin monotherapy in Chinese patients with hypercholesterolemia (ROSE-CH): multicenter, randomized-controlled trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Xianyou","family":"Ji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changjie","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenwen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuebin","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengxu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baisong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuyi","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiufeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaohui","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peijian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqing","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianlong","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongcai","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuiping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"issue":"11","key":"2670_CR1","doi-asserted-by":"publisher","first-page":"e028892","DOI":"10.1161\/JAHA.122.028892","volume":"12","author":"MJ Wilkinson","year":"2023","unstructured":"Wilkinson MJ, Lepor NE, Michos ED. Evolving management of low-density lipoprotein cholesterol: a personalized approach to preventing atherosclerotic cardiovascular disease across the risk continuum. J Am Heart Assoc. 2023;12(11):e028892.","journal-title":"J Am Heart Assoc"},{"key":"2670_CR2","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCN A guideline on the management of blood cholesterol: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines. Circulation. 2019;139(25):e1082-e143.","DOI":"10.1161\/CIR.0000000000000624"},{"key":"2670_CR3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","volume":"290","author":"2019 ESC\/EAS guidelines for the","year":"2019","unstructured":"2019 ESC\/EAS guidelines for the. Management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140\u2013205.","journal-title":"Atherosclerosis"},{"key":"2670_CR4","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.2147\/DDDT.S332352","volume":"16","author":"MR Chilbert","year":"2022","unstructured":"Chilbert MR, VanDuyn D, Salah S, Clark CM, Ma Q. Combination therapy of ezetimibe and rosuvastatin for dyslipidemia: current insights. Drug Des Devel Ther. 2022;16:2177\u201386.","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"2670_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/14779072.2021.1940959","volume":"19","author":"C Boutari","year":"2021","unstructured":"Boutari C, Karagiannis A, Athyros VG. Rosuvastatin and Ezetimibe for the treatment of dyslipidemia and hypercholesterolemia. Expert Rev Cardiovasc Ther. 2021;19(7):575\u201380.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2670_CR6","doi-asserted-by":"crossref","unstructured":"Mostaza JM, Escobar C. Rosuvastatin-based lipid-lowering therapy for the control of LDL cholesterol in patients at high vascular risk. J Clin Med. 2024;13(7).","DOI":"10.3390\/jcm13071894"},{"key":"2670_CR7","doi-asserted-by":"publisher","first-page":"1269172","DOI":"10.3389\/fcvm.2023.1269172","volume":"10","author":"F Omidi","year":"2023","unstructured":"Omidi F, Rahmannia M, Shahidi Bonjar AH, Mohammadsharifi P, Nasiri MJ, Sarmastzadeh T. Ezetimibe and atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Front Cardiovasc Med. 2023;10:1269172.","journal-title":"Front Cardiovasc Med"},{"key":"2670_CR8","doi-asserted-by":"publisher","first-page":"114111","DOI":"10.1016\/j.ejmech.2022.114111","volume":"230","author":"R Zhang","year":"2022","unstructured":"Zhang R, Liu W, Zeng J, Meng J, Jiang H, Wang J, et al. Niemann-Pick C1-Like 1 inhibitors for reducing cholesterol absorption. Eur J Med Chem. 2022;230:114111.","journal-title":"Eur J Med Chem"},{"issue":"12","key":"2670_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11883-015-0550-5","volume":"17","author":"BA Smith","year":"2015","unstructured":"Smith BA, Wright C, Davidson M. Role of ezetimibe in lipid-lowering and cardiovascular disease prevention. Curr Atheroscler Rep. 2015;17(12):72.","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"2670_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40256-020-00421-1","volume":"20","author":"YN Lamb","year":"2020","unstructured":"Lamb YN. Rosuvastatin\/ezetimibe: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2020;20(4):381\u201392.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"2670_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.amjcard.2011.03.079","volume":"108","author":"HE Bays","year":"2011","unstructured":"Bays HE, Davidson MH, Massaad R, Flaim D, Lowe RS, Tershakovec AM, et al. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol. 2011;108(4):523\u201330.","journal-title":"Am J Cardiol"},{"issue":"5","key":"2670_CR12","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/1755-5922.12213","volume":"34","author":"KJ Kim","year":"2016","unstructured":"Kim KJ, Kim SH, Yoon YW, Rha SW, Hong SJ, Kwak CH, et al. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter randomized study of ROsuvastatin and eZEtimibe). Cardiovasc Ther. 2016;34(5):371\u201382.","journal-title":"Cardiovasc Ther"},{"issue":"9","key":"2670_CR13","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.clinthera.2021.07.016","volume":"43","author":"SA Lee","year":"2021","unstructured":"Lee SA, Kim W, Hong TJ, Ahn Y, Kim MH, Hong SJ, et al. Effects of fixed-dose combination of low-intensity rosuvastatin and ezetimibe versus moderate-intensity rosuvastatin monotherapy on lipid profiles in patients with hypercholesterolemia: a randomized, double-blind, multicenter, phase III study. Clin Ther. 2021;43(9):1573\u201389.","journal-title":"Clin Ther"},{"issue":"2","key":"2670_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.clinthera.2017.12.018","volume":"40","author":"SJ Hong","year":"2018","unstructured":"Hong SJ, Jeong HS, Ahn JC, Cha DH, Won KH, Kim W, et al. A phase III, multicenter, randomized, double-blind, active comparator clinical trial to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) randomized controlled trial. Clin Ther. 2018;40(2):226\u201341.e4.","journal-title":"Clin Ther"},{"issue":"12","key":"2670_CR15","doi-asserted-by":"publisher","first-page":"5285","DOI":"10.1007\/s12325-023-02666-z","volume":"40","author":"Q Su","year":"2023","unstructured":"Su Q, Liu Y, Zhang G, Xu L, Wang M, Mei S, et al. Efficacy and safety of single-pill combination of rosuvastatin and ezetimibe in Chinese patients with primary hypercholesterolemia inadequately controlled by statin treatment (ROZEL): a randomized, double-blind, double dummy, active-controlled phase 3 clinical trial. Adv Ther. 2023;40(12):5285\u201399.","journal-title":"Adv Ther"},{"issue":"34","key":"2670_CR16","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","volume":"43","author":"I Byty\u00e7i","year":"2022","unstructured":"Byty\u00e7i I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213\u201323.","journal-title":"Eur Heart J"},{"issue":"5","key":"2670_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.5551\/jat.50435","volume":"27","author":"B Tomlinson","year":"2020","unstructured":"Tomlinson B, Chan P, Liu ZM. Statin intolerance-an Asian perspective. J Atheroscler Thromb. 2020;27(5):485\u201388.","journal-title":"J Atheroscler Thromb"},{"issue":"10","key":"2670_CR18","first-page":"833","volume":"44","author":"adults JciCgftmodi","year":"2016","unstructured":"adults JciCgftmodi. 2016 Chinese guideline for the management of dyslipidemia in adults. Chin J Cardiol. 2016;44(10):833\u201353.","journal-title":"Chin J Cardiol"},{"issue":"12","key":"2670_CR19","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1016\/j.clinthera.2019.10.010","volume":"41","author":"MY Rhee","year":"2019","unstructured":"Rhee MY, Kim KJ, Kim SH, Yoon YW, Rha SW, Hong SJ, et al. Ezetimibe and rosuvastatin combination treatment can reduce the dose of rosuvastatin without compromising its lipid-lowering efficacy. Clin Ther. 2019;41(12):2571\u201392.","journal-title":"Clin Ther"},{"issue":"11","key":"2670_CR20","first-page":"881","volume":"33","author":"T Teramoto","year":"2017","unstructured":"Teramoto T, Yokote K, Nishida C, Oshima N, Takase T. A phase III clinical trial to study the efficacy and safety of ezetimibe plus rosuvastatin combination therapy in Japanese patients with hypercholesterolemia - a randomized, double-blind comparative study. J Clin Therapeut Med. 2017;33(11):881\u201396.","journal-title":"J Clin Therapeut Med"},{"issue":"11","key":"2670_CR21","first-page":"765","volume":"34","author":"T Teramoto","year":"2018","unstructured":"Teramoto T, Yokote K, Nishida C, Oshima N, Takase T. A phase III open-label clinical trial to assess the long-term safety of ezetimibe and rosuvastatin combination therapy in Japanese patients with hypercholesterolemia. J Clin Therapeut Med. 2018;34(11):765\u201382.","journal-title":"J Clin Therapeut Med"},{"issue":"6","key":"2670_CR22","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.clinthera.2018.04.015","volume":"40","author":"W Kim","year":"2018","unstructured":"Kim W, Yoon YE, Shin SH, Bae JW, Hong BK, Hong SJ, et al. Efficacy and safety of ezetimibe and rosuvastatin combination therapy versus those of rosuvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther. 2018;40(6):993\u20131013.","journal-title":"Clin Ther"},{"key":"2670_CR23","doi-asserted-by":"publisher","first-page":"1190934","DOI":"10.3389\/fphar.2023.1190934","volume":"14","author":"JJ Li","year":"2023","unstructured":"Li JJ, Zhao SP, Zhao D, Lu GP, Peng DQ, Liu J, et al. 2023 Chinese guideline for lipid management. Front Pharmacol. 2023;14:1190934.","journal-title":"Front Pharmacol"},{"issue":"8","key":"2670_CR24","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s11883-022-01037-3","volume":"24","author":"L Ferhatbegovi\u0107","year":"2022","unstructured":"Ferhatbegovi\u0107 L, Mr\u0161i\u0107 D, Ku\u0161ljugi\u0107 S, Pojski\u0107 B. LDL-C: the only causal risk factor for ASCVD. Why is it still overlooked and underestimated? Curr Atheroscler Rep. 2022;24(8):635\u201342.","journal-title":"Curr Atheroscler Rep"},{"key":"2670_CR25","doi-asserted-by":"publisher","first-page":"100649","DOI":"10.1016\/j.ajpc.2024.100649","volume":"18","author":"O Mhaimeed","year":"2024","unstructured":"Mhaimeed O, Burney ZA, Schott SL, Kohli P, Marvel FA, Martin SS. The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: lower for longer is better. Am J Prev Cardiol. 2024;18:100649.","journal-title":"Am J Prev Cardiol"},{"key":"2670_CR26","doi-asserted-by":"publisher","first-page":"931931","DOI":"10.3389\/fphys.2022.931931","volume":"13","author":"YN Qiao","year":"2022","unstructured":"Qiao YN, Zou YL, Guo SD. Low-density lipoprotein particles in atherosclerosis. Front Physiol. 2022;13:931931.","journal-title":"Front Physiol"},{"key":"2670_CR27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","volume":"325","author":"M Averna","year":"2021","unstructured":"Averna M, Banach M, Bruckert E, Drexel H, Farnier M, Gaita D, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European atherosclerosis society task force. Atherosclerosis. 2021;325:99\u2013109.","journal-title":"Atherosclerosis"},{"issue":"5","key":"2670_CR28","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.amjcard.2006.10.022","volume":"99","author":"CM Ballantyne","year":"2007","unstructured":"Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007;99(5):673\u201380.","journal-title":"Am J Cardiol"},{"issue":"25","key":"2670_CR29","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"9","key":"2670_CR30","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s11883-024-01225-3","volume":"26","author":"G Bosco","year":"2024","unstructured":"Bosco G, Mszar R, Piro S, Sabouret P, Gallo A. Cardiovascular risk estimation and stratification among individuals with hypercholesterolemia. Curr Atheroscler Rep. 2024;26(9):537\u201348.","journal-title":"Curr Atheroscler Rep"},{"key":"2670_CR31","doi-asserted-by":"crossref","unstructured":"Gaggini M, Gorini F, Vassalle C. Lipids in atherosclerosis: pathophysiology and the role of calculated lipid indices in assessing cardiovascular risk in patients with hyperlipidemia. Int J Mol Sci 2022;24(1).","DOI":"10.3390\/ijms24010075"},{"issue":"Suppl 1","key":"2670_CR32","first-page":"s3","volume":"16","author":"HH Wang","year":"2017","unstructured":"Wang HH, Garruti G, Liu M, Portincasa P, Wang DQ. Cholesterol and lipoprotein metabolism and atherosclerosis: recent advances in reverse cholesterol transport. Ann Hepatol. 2017;16(Suppl 1):s3\u2013105.","journal-title":"Ann Hepatol"},{"key":"2670_CR33","unstructured":"Sizar O, Nassereddin A, Talati R. Ezetimibe. In StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Ali Nassereddin declares no relevant financial relationships with ineligible companies. Disclosure: Raja Talati declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright \u00a9 2025, StatPearls Publishing LLC.; 2025."},{"issue":"1","key":"2670_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s13318-022-00798-1","volume":"48","author":"L Wang","year":"2023","unstructured":"Wang L, Luan Y, Jia C, Xie X, Zhang Z, Xie X, et al. Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: a randomized, phase 1, crossover study in healthy Chinese participants. Eur J Drug Metab Pharmacokinet. 2023;48(1):51\u201362.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"14","key":"2670_CR35","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.2165\/00003495-200262140-00008","volume":"62","author":"CI Carswell","year":"2002","unstructured":"Carswell CI, Plosker GL, Jarvis B. Rosuvastatin Drugs. 2002;62(14):2075\u201385. discussion 86\u2013\u20097.","journal-title":"Rosuvastatin Drugs"},{"issue":"11","key":"2670_CR36","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1517\/13543784.11.11.1587","volume":"11","author":"H Bays","year":"2002","unstructured":"Bays H. Ezetimibe. Expert Opin Investig Drugs. 2002;11(11):1587\u2013604.","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"2670_CR37","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1185\/030079904125004213","volume":"20","author":"T Kosoglou","year":"2004","unstructured":"Kosoglou T, Statkevich P, Yang B, Suresh R, Zhu Y, Boutros T, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin. 2004;20(8):1185\u201395.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"2670_CR38","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1080\/17425255.2020.1801634","volume":"16","author":"T Hirota","year":"2020","unstructured":"Hirota T, Fujita Y, Ieiri I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of Statins. Expert Opin Drug Metab Toxicol. 2020;16(9):809\u201322.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"2670_CR39","first-page":"833","volume":"44","author":"Committee CADPaTGRJ","year":"2016","unstructured":"Committee CADPaTGRJ. Chinese guidelines for the prevention and treatment of dyslipidemia in adults (2016 revised Edition). Chin J Cardiol. 2016;44(10):833\u201353.","journal-title":"Chin J Cardiol"},{"key":"2670_CR40","doi-asserted-by":"crossref","unstructured":"Khatiwada N, Hong Z. Potential benefits and risks associated with the use of statins. Pharmaceutics. 2024;16(2).","DOI":"10.3390\/pharmaceutics16020214"},{"issue":"10349","key":"2670_CR41","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","volume":"400","author":"BK Kim","year":"2022","unstructured":"Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400(10349):380\u201390.","journal-title":"Lancet"},{"issue":"11","key":"2670_CR42","doi-asserted-by":"publisher","first-page":"e0310696","DOI":"10.1371\/journal.pone.0310696","volume":"19","author":"L Liu","year":"2024","unstructured":"Liu L, Deng Y, Li L, Yang X, Yin Z, Lai Y. Efficacy and safety of moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin monotherapy in the treatment of composite cardiovascular events with hypercholesterolemia: a meta-analysis. PLoS ONE. 2024;19(11):e0310696.","journal-title":"PLoS ONE"},{"key":"2670_CR43","doi-asserted-by":"publisher","first-page":"155999","DOI":"10.1016\/j.metabol.2024.155999","volume":"160","author":"H Zhang","year":"2024","unstructured":"Zhang H, Zhou XD, Shapiro MD, Lip GYH, Tilg H, Valenti L, et al. Global burden of metabolic diseases, 1990\u20132021. Metabolism. 2024;160:155999.","journal-title":"Metabolism"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02670-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-025-02670-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02670-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T17:25:15Z","timestamp":1757265915000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-025-02670-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2670"],"URL":"https:\/\/doi.org\/10.1186\/s12944-025-02670-y","relation":{},"ISSN":["1476-511X"],"issn-type":[{"type":"electronic","value":"1476-511X"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study had the approval of the Ethics Committee at each center, with the principal center being Xiangya Second Hospital of Central South University. The ethics approval number provided by the Ethics Committee of Xiangya Second Hospital of Central South University was 2021K191. This study was registered on the Drug Clinical Trial Registration and Information Disclosure Platform with the registration number of CTR20213031.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"249"}}